Resistance to the first line HIV antiretroviral drug dolutegravir is growing and exceeding levels seen in clinical trials, the World Health Organization has warned.1
Surveys conducted in Malawi, Uganda, and Ukraine found that levels of resistance among those receiving dolutegravir based antiretroviral treatment with viral non-suppression ranged from …